Becoming posthuman: hepatitis C, the race to elimination and the politics of remaking the subject

References

• Andaluz, I., del Mar Arcos, M., Montero, M. D., Castillo, P., Martin-Carbonero, L., Garcia-Samaniego, J., & Olveira, A. (2020). Patients with hepatitis C lost to follow-up: Ethical-legal aspects and search results. Revista Espanola de Enfermadades Digestivas (REED), 112(7), 532–538.
   PubMed Web of Science ®Google Scholar
• Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., & Marcellin, P. (2016). Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver International, 36, 47–57.
   PubMed Web of Science ®Google Scholar
• Barad, K. (2007). Meeting the universe halfway: Quantum physics and the entanglement of matter and meaning. Durham: Duke University Press.
   Google Scholar
• Berg, J., Appelbaum, P., Lidz, C., & Parker, S. (2001). Informed consent: Legal theory and clinical practice. New Jersey: Oxford University Press.
   Google Scholar
• Butler, J. (2004). Undoing gender. New York and London: Routledge.
   Google Scholar
• Cohn, S., & Lynch, R. (2017). Posthuman perspectives: Relevance for a global public health. Critical Public Health, 27(3), 285–292.
   Web of Science ®Google Scholar
• Commonwealth Department of Health. (2017). National drug strategy 2017-2026. Canberra: Commonwealth of Australia.
   Google Scholar
• Commonwealth Department of Health. (2018). Fifth national hepatitis C strategy 2018-2022. Canberra: Department of Health.
   Google Scholar
• Commonwealth Department of Health and Aged Care. (2000). National hepatitis c strategy 1999-2000 to 2003-2004. Canberra: Commonwealth Department of Health and Aged Care.
   Google Scholar
• Commonwealth Department of Health and Ageing. (2005). National hepatitis C strategy 2005-2008. Canberra: Commonwealth of Australia.
   Google Scholar
• Commonwealth of Australia. (2020). National hepatitis c testing strategy. Canberra: Commonwealth of Australia.
   Google Scholar
• Crane, D., Henderson, E. J., & Chadwick, D. R. (2017). Exploring the acceptability of a ‘limited patient consent procedure’ for a proposed blood-borne virus screening programme: A Delphi consensus building technique. BMJ Open, 7(5), e015373.
   PubMed Web of Science ®Google Scholar
• Deleuze, G., & Parnet, C. (1987). Dialogues. London: Athlone Press.
   Google Scholar
• Dencik, L. (2020). Advancing data justice in public health and beyond. The American Journal of Bioethics, 20(10), 32–33. doi:https://doi.org/10.1080/15265161.2020.1806945
   PubMed Web of Science ®Google Scholar
• Dennis, F. (2019). Injecting bodies in more-than-human worlds. London: Routledge.
   Google Scholar
• Dilkes-Frayne, E., & Duff, C. (2017). Tendencies and trajectories: The production of subjectivity in an event of drug consumption. Environment and Planning D: Society and Space, 35(5), 951–967.
   Web of Science ®Google Scholar
• Dore, G. (2017). Australia leads the world in hepatitis C treatment – What's behind its success? The Conversation, July 21.
   Google Scholar
• Duff, C. (2014). The place and time of drugs. International Journal of Drug Policy, 25, 633–639.
   PubMed Web of Science ®Google Scholar
• Duff, C. (2017). Critical drug studies after the ontological turn. Contemporary Drug Problems conference, August, Helsinki: Finland.
   Google Scholar
• European Association for the Study of the Liver. (2018). EASL recommendations on treatment of hepatitis C 2018. Journal of Hepatology, 69, 461–511.
   PubMed Web of Science ®Google Scholar
• Farrugia, A. (2017). Gender, reputation and regret: The ontological politics of Australian drug education. Gender and Education, 29(3), 281–298.
   Web of Science ®Google Scholar
• Fitzgerald, J. (2015). Framing drug use: Bodies, space, economy and crime. Basingstoke: Palgrave Macmillan.
   Google Scholar
• Francis-Graham, S., Ekeke, N. A., Nelson, C. A., Lee, T. Y., El Haj, S., Rhodes, T., & Rosenberg, W. (2019). Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: A rapid-realist review. BMC Health Services Research, 19(1), 1–18.
   PubMedGoogle Scholar
• Fraser, S. (2006). The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects. International Journal of Drug Policy, 17(3), 192–202.
   Web of Science ®Google Scholar
• Fraser, S. (In press). Doing ontopolitically-oriented research: Synthesising concepts from the ontological turn for alcohol and other drug research and other social sciences. International Journal of Drug Policy, 82.
   PubMed Web of Science ®Google Scholar
• Fraser, S., & Moore, D. (2011a). Harm reduction and hepatitis C: On the ethics and politics of prevention and treatment. Addiction Research and Theory, 19(4), 375–379.
   Web of Science ®Google Scholar
• Fraser, S., & Moore, D. (2011b). The drug effect: Health crime and society. Melbourne: Cambridge University Press.
   Google Scholar
• Fraser, S., Pienaar, K., Dilkes-Frayne, E., Moore, D., Kokanovic, R., Treloar, C., & Dunlop, A. (2017). Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis. International Journal of Drug Policy, 44, 192–201.
   PubMed Web of Science ®Google Scholar
• Fraser, S., & Seear, K. (2011). Making disease, making citizens: The politics of hepatitis C. Aldershot: Ashgate.
   Google Scholar
• Gane, E. (2014). Hepatitis C beware – The end is nigh. The Lancet, 384(9954), 1557–1560.
   PubMed Web of Science ®Google Scholar
• Hajarizadeh, B., Grebely, J., Martinello, M., Matthews, G., Lloyd, A., & Dore, G. (2016). Hepatitis C treatment as prevention: Evidence, feasibility, and challenges. Lancet: Gastroenterology and Hepatology, 1, 317–327.
   PubMed Web of Science ®Google Scholar
• Harris, M., Albers, E., & Swan, T. (2015). The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? International Journal of Drug Policy, 26, 963–969.
   PubMed Web of Science ®Google Scholar
• Hellard, M. (2014). Eliminating hepatitis C – an ambitious but achievable goal. The Conversation. March 28.
   Google Scholar
• Hellard, M. D., Rolls, A., Sacks-Davis, R., Robins, G., Pattison, P., Higgs, P., … McBryde, E. (2014). The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology, 60(6), 1861–1870.
   PubMed Web of Science ®Google Scholar
• Hopwood, M., & Treloar, C. (2007). Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. Journal of Advanced Nursing, 59(3), 248–254.
   PubMed Web of Science ®Google Scholar
• Johnson, J., & Lenton, E. (2017). HIV and hepatitis pre- and post-test discussion in Victoria consultation report. Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University.
   Google Scholar
• Kracht, P. A. M., Arends, J. E., van Erpecum, K. J., Thijsen, S. F. T., Vlaminckx, B. J. M., Weersink, A. J. L., … Hoepelman, A. I. M. (2019). REtrieval And cure of Chronic Hepatitis C (REACH): results of micro-elimination in the Utrecht province. Liver International, 39(3), 455–462.
   PubMed Web of Science ®Google Scholar
• Lancaster, K., & Rhodes, T. (In press). Futuring a world without disease: Visualising the elimination of hepatitis C. Critical Public Health, 1–15.
   PubMed Web of Science ®Google Scholar
• Lancaster, K., Seear, K., & Ritter, A. (2018). Reducing stigma and discrimination for people experiencing problematic alcohol and other drug use. Drug policy modelling program monograph series, 26. Sydney: National Drug and Alcohol Research Centre.
   Google Scholar
• Lazarus, J. V., Safreed-Harmon, K., Thursz, M. R., Dillon, J. F., El-Sayed, M. H., Elsharkawy, A. M., & Colombo, M. (2018). The micro-elimination approach to eliminating hepatitis C: Strategic and operational considerations. In Seminars in liver disease (Vol. 38, No. 03, pp. 181-192). Thieme Medical Publishers.
   Google Scholar
• Lloyd, C. (2010). Sinning and sinned against: The stigmatisation of problem drug users. London: UK Drug Policy Commission.
   Google Scholar
• MacLachlan, J. H., Smith, C., Towell, V., & Cowie, B. C. (2020). Viral hepatitis mapping project: National report 2018–19. Darlinghurst: Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). https://ashm.org.au/programs/Viral-Hepatitis-Mapping-Project/.
   Google Scholar
• Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018a). Beyond cure: Patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduction Journal, 15(1), 1–8.
   PubMedGoogle Scholar
• Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018b). Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PloS one, 13(11), e0207226.
   PubMed Web of Science ®Google Scholar
• Malins, P. (2017). Desiring assemblages: A case for desire over pleasure in critical drug studies. International Journal of Drug Policy, 49, 126–132.
   PubMed Web of Science ®Google Scholar
• Martinello, M., Hajarizadeh, B., & Dore, G. J. (2018). Observations on the launch of new drugs for hepatitis C. Australian Prescriber, 41(1), 4.
   PubMed Web of Science ®Google Scholar
• Martinello, M., & Matthews, G. V. (2015). Enhancing the detection and management of acute hepatitis C virus infection. International Journal of Drug Policy, 26(10), 899–910.
   PubMed Web of Science ®Google Scholar
• Moore, D., & Fraser, S. (2006). Putting at risk what we know: Reflecting on the drug-using subject in harm reduction and its political implications. Social Science and Medicine, 62, 3035–3047.
   PubMed Web of Science ®Google Scholar
• Newman, C., MacGibbon, J., Smith, A. K., Broady, T., Lupton, D., Davis, M., & Holt, M. (2020). Understanding trust in digital health among communities affected by BBVs and STIs in Australia. Sydney: UNSW.
   Google Scholar
• O’Kelly, M., Byrne, D., Naughten, E., Bergin, C., & Williams, C. (2016). Opt-out testing for blood-borne viruses in primary care: A multicentre, prospective study. British Journal of General Practice, 66(647), e392–e396.
   PubMed Web of Science ®Google Scholar
• Persson, A., Newman, C. E., Mao, L., & de Wit, J. (2016). On the margins of pharmaceutical citizenship: Not taking HIV medication in the “treatment revolution” era. Medical Anthropology Quarterly, 30(3), 359–377.
   PubMed Web of Science ®Google Scholar
• Prince, D. S., Pipicella, J. L., Fraser, M., Alvaro, F., Maley, M., Foo, H., & Levy, M. T. (2021). Screening emergency admissions at risk of chronic hepatitis C (SEARCH) to diagnose or ‘re-diagnose’ infections is effective in Australia. Journal of Viral Hepatitis, 28(1), 121–128.
   PubMed Web of Science ®Google Scholar
• Rance, J., Rhodes, T., & Lancaster, K. (2021). Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits. Health: An interdisciplinary journal for the social study of health, illness and medicine. Early online.
   Google Scholar
• Rhodes, T., & Treloar, C. (2008). The social production of hepatitis C risk among injecting drug users: A qualitative synthesis. Addiction, 103(10), 1593–1603.
   PubMed Web of Science ®Google Scholar
• Scott, N., Sacks-Davis, R., Wade, A. J., Stoove, M., Pedrana, A., Doyle, J. S., & Hellard, M. E. (2020). Australia needs to increase testing to achieve hepatitis C elimination. Medical Journal of Australia, 212(8), 365–370.
   PubMed Web of Science ®Google Scholar
• Seear, K., Fraser, S., Farrugia, A., & Valentine, K. (In press). Beyond a ‘post-cure’ world: Sketches for a new futurology of hepatitis C. International Journal of Drug Policy. Early online
   Web of Science ®Google Scholar
• Stoové, M., Wallace, J., Higgs, P., Pedrana, A., Goutzamanis, S., Latham, N., … Hellard, M. (2020). Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. International Journal of Drug Policy, 75, 102596.
   PubMed Web of Science ®Google Scholar
• Treloar, C., Rance, J., & Backmund, M. (2013). Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clinical Infectious Diseases, 57(suppl_2), S51–S55.
   PubMed Web of Science ®Google Scholar
• Treloar, C., & Rhodes, T. (2009). The lived experience of hepatitis C and its treatment among injecting drug users: Qualitative synthesis. Qualitative Health Research, 19(9), 1321–1334.
   PubMed Web of Science ®Google Scholar
• Van Dijk, M., van Agt, F. M., & Drenth, J. P. H. (2020). Legal and ethical challenges in developing a Dutch nationwide hepatitis C retrieval project (CELINE). International Journal of Health Policy Management, x(x), 1–5.
   Google Scholar
• Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2018). Hepatitis C in a new therapeutic era: Recontextualising the lived experience. Journal of Clinical Nursing, 27(13-14), 2729–2739.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2016). Combating hepatitis B and C to reach elimination by 2030. Geneva: WHO.
   Google Scholar
• World Health Organization. (2016). Global health sector strategy on viral hepatitis: Towards ending viral hepatitis, 2016-2021. Geneva: World Health Organization.
   Google Scholar
• World Health Organization. (2017). WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization.
   Google Scholar
• Wright, C., Cogger, S., Hsieh, K., Goutzamanis, S., Hellard, M., & Higgs, P. (2019). “I'm obviously not dying so it's not something I need to sort out today”: considering hepatitis C treatment in the era of direct acting antivirals. Infection, Disease and Health, 24(2), 58–66.
   PubMed Web of Science ®Google Scholar